candesartan has been researched along with Adenocarcinoma in 5 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The effects of AT1 receptor blocker candesartan were evaluated in a mouse model of peritoneal carcinomatosis." | 3.75 | Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. ( Fujimura, T; Fujita, H; Fushida, S; Harada, S; Hirakawa, K; Kayahara, M; Kinami, S; Kinoshita, J; Ninomiya, I; Ohta, T; Yagi, Y; Yashiro, M, 2009) |
| "Candesartan treatment was associated with increased iNOS expression (p = ." | 2.84 | Support for involvement of the renin-angiotensin system in dysplastic Barrett's esophagus. ( Bratlie, SO; Casselbrant, A; Edebo, A; Fändriks, L, 2017) |
| "Candesartan treatment also inhibits the expression of anti-apoptotic protein c-FLIP." | 1.48 | Antihypertensive drug-candesartan attenuates TRAIL resistance in human lung cancer via AMPK-mediated inhibition of autophagy flux. ( Park, SY; Rasheduzzaman, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rasheduzzaman, M | 1 |
| Park, SY | 1 |
| Bratlie, SO | 1 |
| Casselbrant, A | 1 |
| Edebo, A | 1 |
| Fändriks, L | 1 |
| Kinoshita, J | 1 |
| Fushida, S | 1 |
| Harada, S | 1 |
| Yagi, Y | 1 |
| Fujita, H | 1 |
| Kinami, S | 1 |
| Ninomiya, I | 1 |
| Fujimura, T | 1 |
| Kayahara, M | 1 |
| Yashiro, M | 1 |
| Hirakawa, K | 1 |
| Ohta, T | 1 |
| Suganuma, T | 1 |
| Ino, K | 1 |
| Shibata, K | 1 |
| Kajiyama, H | 1 |
| Nagasaka, T | 1 |
| Mizutani, S | 1 |
| Kikkawa, F | 1 |
| Uemura, H | 1 |
| Hasumi, H | 1 |
| Kawahara, T | 1 |
| Sugiura, S | 1 |
| Miyoshi, Y | 1 |
| Nakaigawa, N | 1 |
| Teranishi, J | 1 |
| Noguchi, K | 1 |
| Ishiguro, H | 1 |
| Kubota, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for candesartan and Adenocarcinoma
| Article | Year |
|---|---|
Support for involvement of the renin-angiotensin system in dysplastic Barrett's esophagus.
Topics: Adenocarcinoma; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2017 |
Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Age | 2005 |
3 other studies available for candesartan and Adenocarcinoma
| Article | Year |
|---|---|
Antihypertensive drug-candesartan attenuates TRAIL resistance in human lung cancer via AMPK-mediated inhibition of autophagy flux.
Topics: Adenocarcinoma; Antihypertensive Agents; Apoptosis; Autophagy; Benzimidazoles; Biphenyl Compounds; C | 2018 |
Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Angiotensin II; A | 2009 |
Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Topics: Adenocarcinoma; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antigens, CD34; Be | 2005 |